Fenwick & West represented Seattle Genetics, Inc. (NASDAQ: SGEN), in an immuno-oncology collaboration with Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company that discovers and develops Anticalin-based drugs to target validated disease pathways in a unique and transformative way. Through this collaboration, the companies will pair their respective technologies to develop new immuno-oncology treatments for solid tumors and blood cancers.
The Fenwick transaction team was led by Stefano Quintini with support from technology transaction lawyer Amy Manning and antitrust partner Mark Ostrau.